CY1113344T1 - Use of IL-21 in Cancer and Monoclonal Antibodies for Solid Cancer Therapeutic Treatment - Google Patents
Use of IL-21 in Cancer and Monoclonal Antibodies for Solid Cancer Therapeutic TreatmentInfo
- Publication number
- CY1113344T1 CY1113344T1 CY20121100454T CY121100454T CY1113344T1 CY 1113344 T1 CY1113344 T1 CY 1113344T1 CY 20121100454 T CY20121100454 T CY 20121100454T CY 121100454 T CY121100454 T CY 121100454T CY 1113344 T1 CY1113344 T1 CY 1113344T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cancer
- monoclonal antibodies
- therapeutic treatment
- molecules
- solid
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000012830 cancer therapeutic Substances 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 230000005714 functional activity Effects 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Περιγράφονται μέθοδοι για τη θεραπευτική αγωγή θηλαστικών με καρκίνο και μολύνσεις χρησιμοποιώντας μόρια που έχουν μια λειτουργική δραστικότητα της IL-21. Τα μόρια που έχουν λειτουργικές δραστικότητες της IL-21 περιλαμβάνουν πολυπεπτίδια που έχουν ομολογία προς την ανθρώπινη IL 21 πολυπεπτιδική αλληλουχία και πρωτεΐνες συντηγμένες προς ένα πολυπεπτίδιο με λειτουργική δραστικότητα της IL-21. Τα μόρια μπορούν να χρησιμοποιηθούν ως μονοθεραπεία ή σε συνδυασμό με άλλες γνωστές θεραπευτικές αγωγές καρκίνου ή ιϊκές θεραπευτικές αγωγές.Methods are described for the treatment of mammals with cancer and infections using molecules that have a functional activity of IL-21. Molecules having IL-21 functional activities include polypeptides that have homology to the human IL 21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as monotherapy or in combination with other known cancer treatments or viral treatments.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38712702A | 2002-06-07 | 2002-06-07 | |
| EP03757366A EP1531850B1 (en) | 2002-06-07 | 2003-06-06 | Use of IL-21 and monoclonal antibody for treating solid cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1113344T1 true CY1113344T1 (en) | 2016-06-22 |
Family
ID=58448866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100454T CY1113344T1 (en) | 2002-06-07 | 2012-05-16 | Use of IL-21 in Cancer and Monoclonal Antibodies for Solid Cancer Therapeutic Treatment |
Country Status (1)
| Country | Link |
|---|---|
| CY (1) | CY1113344T1 (en) |
-
2012
- 2012-05-16 CY CY20121100454T patent/CY1113344T1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004011770D1 (en) | FUSION PROTEIN | |
| CY1120070T1 (en) | METHOD OF THERAPEUTIC TREATMENT WITH THE USE OF ANTI-ERBB-METHYSINEOID ANTIBODY conjugates | |
| BR0008161A (en) | Use of a therapeutic composition for treating a tumor cell, therapeutic composition, and kit for treating a tumor cell | |
| DK1368060T3 (en) | HMGB1 protein inhibitors and / or antagonists for the treatment of vascular disease | |
| DE60032486D1 (en) | PRION PROTEIN PEPTIDES AND ITS USE | |
| EA200001023A1 (en) | SPECIFIC FOR FAPA- (PROTEIN ALPHA FIBROBE ACTIVATION) ANTIBODY WITH INCREASED PRODUCTIVITY | |
| DK0914144T3 (en) | Therapeutic uses of BPI protein products for human meningococcemia | |
| EA200100749A1 (en) | SYNTHETIC PEPTIDES OWN SURFACE ACTIVITY AND THEIR APPLICATION FOR THE PREPARATION OF THE SYNTHETIC SURFACTANT | |
| CY1117387T1 (en) | Monoclonal N-11 Dispersed β-Amyloid Antibodies, COMPOSITIONS, METHODS AND USES | |
| CY1105616T1 (en) | PEPTIDE INHIBITORS OF TGFβ1 | |
| CY1112639T1 (en) | ORTHOLOGICALLY DESIGNED ANTIBODIES | |
| HUP9802212A2 (en) | Recombinant anti-cd4 antibodies for human therapy | |
| CY1107628T1 (en) | HUMAN CTLA-4 ANTIBODIES AND USES | |
| CR7875A (en) | IMMUNOGLOBIN VARIANTS AND USES OF THIS | |
| EA200500218A1 (en) | TREATMENT OF KIDNEY INSUFFICIENCY WITH THE USE OF INTERFERON-β | |
| CY1108459T1 (en) | AKT-3 NUCLEAR ACIDS, POLYPALPTESES, AND THEIR USES | |
| ATE354638T1 (en) | HUMAN TISSUE INHIBITOR OF METALLOPROTEINASE-4 | |
| CY1111371T1 (en) | BAG3 ANTIBODIES FOR USE IN RESEARCH, DIAGNOSIS AND TREATMENT OF DISEASES RELATING TO CELLULAR DEATH | |
| MXPA05008704A (en) | Fusion proteins of interferon alpha muteins with improved properties. | |
| BR9509172A (en) | Native complement pathway protein DNA sequence construction of conjugated dna use of a process protein to reduce complement pathway protein in a mammal and pharmaceutical formulation | |
| ATE450272T1 (en) | BORDETELLA RECOMBINANT ADENYLATE CYCLASE TOXIN INDUCES T CELL RESPONSES AGAINST TUMORAL ANTIGENS | |
| ATE368687T1 (en) | THROMBOPOIETIN PROTEINS WITH IMPROVED PROPERTIES | |
| IT1249684B (en) | HEPATITIS VIRUS PROTEIN ENV EPITOPES | |
| CY1113344T1 (en) | Use of IL-21 in Cancer and Monoclonal Antibodies for Solid Cancer Therapeutic Treatment | |
| TR199902866T2 (en) | New BPC peptide salts with organoprotective activity, processes for their preparation and use in therapy. |